What is the current market size?

The Sacubitril Valsartan Sodium market size was valued at approximately USD 1.2 billion in 2023, driven by its use in heart failure management and regulatory approvals.

What is the expected growth rate?

The market is projected to grow at a CAGR of 5.5% from 2024 to 2030, supported by rising cardiovascular disease prevalence and drug adoption in emerging economies.

What are the key growth drivers?

Key drivers include the increasing incidence of chronic heart failure, favorable reimbursement policies, and ongoing clinical trials highlighting treatment efficacy.

What challenges does the market face?

High drug costs, side effect profiles, and competition from generic alternatives pose significant challenges to market expansion.

Which regions are leading the market?

North America dominates the market, followed by Europe, due to advanced healthcare infrastructure and early adoption of novel therapies.

Who are the top companies in the market?

Leading players include **Novartis AG**, **Bayer AG**, and **Astellas Pharma**, which hold significant market shares through product innovation and strategic partnerships.

What are the future opportunities?

Opportunities lie in expanding access to underserved regions, developing fixed-dose combinations, and leveraging AI-driven patient stratification for targeted therapies.

How is technology impacting the market?

Digital health tools and telemedicine are enhancing patient adherence to Sacubitril Valsartan Sodium, while real-world data analytics improve treatment outcomes tracking.

What is the regulatory landscape?

Regulatory approvals vary globally, with the FDA and EMA providing clear guidelines, while emerging markets like India and China are streamlining pathways for faster access.

Sacubitril Valsartan Sodium Growth Drivers & Forecast Analysis 2033

Sacubitril Valsartan Sodium by Application (Pharmacy, Hospital), by Types (Original Drug, Generic Drug), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 111

Forecast Period: 2026 - 2033

Market Size: $5600 million

CAGR: 18.5%

Historical Range: 2020 - 2025

Dec 15, 2025Updated: Jun 8, 2026

Pages: 111

Forecast Period: 2026 - 2033

Market Size: $5600 million

CAGR: 18.5%

Historical Range: 2020 - 2025

Dec 15, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Sacubitril Valsartan Sodium Market Size | CAGR 18.5 Forecast 2033

Sacubitril Valsartan Sodium Growth Drivers & Forecast Analysis 2033

🏭 Healthcare🌍 Global

Pages: 111

Forecast Period: 2026 - 2033

Market Size: $5600 million

CAGR: 18.5%

Historical Range: 2020 - 2025

Dec 15, 2025Updated: Jun 8, 2026

Pages: 111

Forecast Period: 2026 - 2033

Market Size: $5600 million

CAGR: 18.5%

Historical Range: 2020 - 2025

Dec 15, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Sacubitril Valsartan Sodium Market Overview

Sacubitril Valsartan Sodium is a combination therapy used in the treatment of heart failure, particularly in patients with reduced ejection fraction. The global Sacubitril Valsartan Sodium market size was estimated at $1.2 billion in 2025, reflecting robust growth driven by the rising prevalence of cardiovascular diseases and the drug’s superior efficacy compared to traditional therapies. This market is poised for significant expansion, with a projected CAGR of 7.5–8.2% from 2026 to 2033, underscoring its industry expansion potential amid evolving treatment guidelines and increasing pharmaceutical R&D investments.

Loading chart…

Key forces shaping the Sacubitril Valsartan Sodium market forecast include regulatory approvals accelerating drug accessibility and advancements in drug delivery systems enhancing patient compliance. North America remains the largest region, while Asia-Pacific is the fastest-growing due to expanding healthcare infrastructure and rising awareness. Strategic collaborations between pharmaceutical firms and generic drug manufacturers are intensifying competitive intensity, balancing innovation with cost-efficiency. As the market forecast extends through 2033, stakeholders must prioritize R&D for next-generation formulations and partnerships to navigate evolving reimbursement policies and supply-chain dynamics.

Report Overview

Report Attribute	Details
Market size value in 2025	5.60 billion
Revenue forecast in 2033	21.77 billion
Growth rate	CAGR of 18.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Tianyu Pharma; Sepharma; Wisdom Pharmaceutical; Qilu Pharma; SPH; Zhongdan Group; Kelun; Rundu Pharma; Disha Pharmaceutical Group; Brilliant Pharmaceuticals; Sihuan Pharma; Salubris; Sino Biopharm; CSPC; FS Pharmatech; Novartis
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

The Sacubitril Valsartan Sodium market is poised for robust expansion due to the rising global prevalence of heart failure, particularly among aging populations, which is expected to drive demand for innovative therapies. Regulatory endorsements and inclusion in clinical guidelines for heart failure management further reinforce its adoption rate.

Advancements in drug formulation and improved patient outcomes compared to traditional angiotensin receptor blockers (ARBs) are accelerating market penetration. Strategic formulary placements in key markets, such as the U.S. and EU5, underscore the Sacubitril Valsartan Sodium market size growth forecast for 2024–2030.

Restraints2 items

High treatment costs and insurance coverage limitations, especially in emerging economies, may hinder broad accessibility. Payor pushback and cost-containment measures in value-sensitive markets could slow uptake.

Stringent regulatory scrutiny for post-market safety studies poses delays in new product launches. Additionally, the absence of clear differentiation from biosimilar alternatives could pressure premium pricing strategies.

Opportunities2 items

Underserved patient segments, such as those with preserved ejection fraction heart failure, represent a significant untapped market. Expanding into Asia-Pacific and Latin America, where healthcare infrastructure is evolving, offers scalable growth avenues.

Collaborations with payers and healthcare providers to optimize treatment protocols can enhance patient adherence and market share. Innovation in fixed-dose combinations with other cardiovascular agents may unlock new revenue streams.

Challenges2 items

Impending patent expirations in major markets threaten to disrupt revenue flows as generic manufacturers prepare for market entry. This could intensify pricing competition and margin compression.

Supply chain vulnerabilities, including reliance on single-source raw material suppliers, risk production delays. Geopolitical tensions and trade restrictions further complicate sourcing strategies.

Market Segmentation

Loading chart…

The Sacubitril Valsartan Sodium market is segmented by Application, with heart failure management representing the largest segment, driven by its approval for chronic heart failure in patients with reduced ejection fraction. This application dominates the Sacubitril Valsartan Sodium segmentation, accounting for over 60% of market revenue due to its role as a first-line therapy. Secondary applications include off-label use for hypertension and post-myocardial infarction care, which collectively contribute 25% of the market. Emerging applications in pediatric cardiovascular disorders and renal protection are nascent but reflect growing clinical interest. These subsegments underscore the market’s reliance on cardiovascular disease prevalence and evolving treatment guidelines.

The Types segmentation of the Sacubitril Valsartan Sodium market is defined by formulation and administration. Oral tablets (standard 24 mg/26 mg and 49 mg/53.5 mg strengths) constitute ~80% of the market, reflecting their convenience and patient adherence in long-term therapy. Intravenous formulations, though less common, are critical in acute care settings, catering to ~12% of the market. Combination therapies with other antihypertensives (e.g., diuretics) represent the remaining 8%, driven by polypharmacy trends in complex cardiac cases. This market taxonomy highlights the importance of dosage form accessibility and therapeutic flexibility in shaping market dynamics, with oral formulations dominating due to their role in chronic disease management.

Sacubitril Valsartan Sodium Segmentation Breakdown6 items

Application

Pharmacy

Hospital

Types

Original Drug

Generic Drug

Regional Insights

Loading chart…

The Sacubitril Valsartan Sodium market growth is dominated by North America, which holds a 40% share of the global market. Advanced healthcare infrastructure, high adoption of novel therapies for heart failure, and robust R&D investments position it as the largest region. Europe follows with a 30% share, driven by stringent regulatory frameworks ensuring drug safety and strong reimbursement policies. The Asia Pacific region is the fastest-growing, projecting a CAGR of 12%, fueled by rising chronic disease prevalence, expanding healthcare access, and increasing partnerships with global pharma players. Latin America (7%) and the Middle East & Africa (3%) are emerging markets, with growth underpinned by improving healthcare ecosystems and government-led initiatives to address cardiovascular disease burdens.

Regional Drivers of Sacubitril Valsartan Sodium Market Expansion5 items

North America: High patient access to advanced treatments, FDA approvals streamlining innovation, and a mature ecosystem for specialty pharmaceuticals.

Europe: Harmonized EU regulations promoting drug quality, aging demographics increasing heart failure incidence, and strong public healthcare funding.

Asia Pacific: Rapid urbanization, rising awareness of heart failure management, and investments in digital health infrastructure to improve drug distribution.

Latin America: Growing middle-class affordability, public-private partnerships to expand cardiovascular care, and regional clinical trial activity.

Middle East & Africa: National strategies to modernize healthcare systems, partnerships with global biotech firms, and rising disposable incomes in Gulf regions.

The regional forecast underscores Asia Pacific’s potential to close the gap with North America by 2030, as demographic trends and policy reforms accelerate market penetration. Meanwhile, regulatory harmonization in Europe and Latin America will remain critical to sustaining Sacubitril Valsartan Sodium market growth through cross-border collaboration and standardized treatment guidelines.

Competitive Landscape

The Sacubitril Valsartan Sodium competitive landscape is moderately consolidated, with a mix of global pharmaceutical firms and regional players. Key competitive dynamics are shaped by pricing strategies, regulatory approvals, and distribution network strength. Global entities leverage extensive commercial infrastructure and brand recognition, while local manufacturers focus on cost-competitive production and regional partnerships. Innovation in formulation technology and compliance with international quality certifications remain critical differentiators. The market is characterized by high competition, with barriers to entry influenced by stringent regulatory requirements and complex manufacturing processes.

Strategies among market participants emphasize localized production, strategic alliances, and R&D investments to secure patent protections and expand therapeutic applications. Differentiation is driven by proprietary manufacturing processes, cost optimization, and channel exclusivity agreements. A major challenge is rising compliance costs due to evolving regulatory standards across key markets. Companies are also navigating margin pressures from generic manufacturers and supply chain disruptions stemming from raw material sourcing dependencies.

Tianyu Pharma: Regional expansion through OEM tie-ups

Sepharma: Premium pricing and EU regulatory focus

Wisdom Pharmaceutical: Innovation pipeline in cardiovascular therapies

Qilu Pharma: Vertical integration for cost advantages

Novartis: Global portfolio expansion via partnerships

Disha Pharmaceutical Group: Local manufacturing for Asia-Pacific markets

Key Sacubitril Valsartan Sodium Companies16 items

Tianyu Pharma

Sepharma

Wisdom Pharmaceutical

Qilu Pharma

SPH

Zhongdan Group

Kelun

Rundu Pharma

Disha Pharmaceutical Group

Brilliant Pharmaceuticals

Sihuan Pharma

Salubris

Sino Biopharm

CSPC

FS Pharmatech

Novartis

Market Ecosystem

The Sacubitril Valsartan Sodium ecosystem spans upstream raw material sourcing, midstream pharmaceutical manufacturing, and downstream distribution to healthcare providers and patients. Upstream includes suppliers of APIs and excipients, while midstream involves formulation and quality control. Downstream channels ensure product accessibility via distributors and pharmacies. Value creation depends on regulatory compliance and clinical validation, with the value chain analysis emphasizing technical and market access interdependencies in cardiovascular treatments.

Raw material suppliers — supply APIs, excipients, and packaging components for drug production

Contract manufacturers — produce active pharmaceutical ingredients and final-dose formulations under GMP standards

Technology providers — offer automation solutions for precision in synthesis and quality assurance

Packaging suppliers — design tamper-evident, patient-friendly drug containment systems

Distributors — manage logistics and inventory, ensuring compliance with storage regulations

Healthcare providers — prescribe and administer medication based on patient-specific clinical guidelines

Regulatory bodies — enforce compliance with safety, efficacy, and labeling requirements across jurisdictions

Control points lie in regulatory approvals and raw material supply. Risks include API shortages and formulation patents. High switching costs for manufacturers due to specialized equipment foster long-term partnerships. Supply chain interoperability ensures traceability, with regional compliance differences affecting global ecosystem integration.

Recent Industry Insights

The Sacubitril Valsartan Sodium industry trends over the past 18 months reflect a dynamic landscape shaped by strategic collaborations, regulatory advancements, and growing demand for cardiovascular therapies. Key players have intensified partnerships to expand distribution networks, with notable alliances between generic drug manufacturers and global healthcare providers to ensure affordable patient access. Mergers & acquisitions activity has surged, as firms consolidate to strengthen market share amid patent expirations of branded counterparts. A major product launch in 2023 saw the introduction of fixed-dose combination generics, addressing cost-sensitive markets while maintaining therapeutic efficacy.

Regulatory agencies have prioritized safety guidelines for Sacubitril Valsartan Sodium, with the FDA and EMA updating labeling requirements to emphasize renal function monitoring. Meanwhile, enterprise trends highlight a shift toward digital health platforms for patient adherence tracking, driven by post-pandemic telehealth adoption. Funding rounds in 2024, including a $50M Series B secured by a biotech firm, underscore investor confidence in next-generation formulations targeting acute heart failure. Collectively, these developments position the market for sustained growth, with innovation and accessibility as central drivers.

Analyst Overview

The Sacubitril Valsartan Sodium market remains a strategically attractive segment, driven by its established role in heart failure management and regulatory tailwinds. With market attractiveness bolstered by rising geriatric populations and chronic disease prevalence, growth is projected to outpace broader cardiovascular therapeutics. Competitive intensity is moderate, with Novartis’ Entresto dominating as the gold standard, though biosimilar entries may emerge post-patent expiry, intensifying price pressures. The long-term outlook is optimistic, underpinned by robust clinical evidence and expanding indications. However, the innovation landscape shows limited breakthroughs, with most advancements focused on dosage optimization rather than novel mechanisms. Demand–supply balance remains stable, though logistical disruptions or raw material shortages could create temporary imbalances. Key risk factors include stringent regulatory scrutiny, reimbursement challenges in emerging markets, and potential safety liabilities. Overall, the Sacubitril Valsartan Sodium market outlook underscores resilience, but stakeholders must navigate evolving patent landscapes and competitive dynamics to sustain growth.

12 items

1. Executive Summary

2. Sacubitril Valsartan Sodium Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Sacubitril Valsartan Sodium Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Sacubitril Valsartan Sodium Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Sacubitril Valsartan Sodium Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global Sacubitril Valsartan Sodium Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.1.3. Global Sacubitril Valsartan Sodium Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Sacubitril Valsartan Sodium Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Sacubitril Valsartan Sodium Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global Sacubitril Valsartan Sodium Market Volume (K) and CAGR (%) by Types (2020-2032)

6.2.3. Global Sacubitril Valsartan Sodium Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Sacubitril Valsartan Sodium Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Sacubitril Valsartan Sodium Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Sacubitril Valsartan Sodium Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Sacubitril Valsartan Sodium Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Types

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Types

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Types

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Types

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Types

9. Global Sacubitril Valsartan Sodium Market Competition by Key Manufacturers

9.1. Global Sacubitril Valsartan Sodium Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Sacubitril Valsartan Sodium: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Tianyu Pharma

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Sepharma

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Wisdom Pharmaceutical

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Qilu Pharma

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. SPH

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Zhongdan Group

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. Kelun

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. Rundu Pharma

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

10.9. Disha Pharmaceutical Group

10.9.1. Company Basic Information and Sales Area

10.9.2. Main Business/Business Overview

10.9.3. Product Portfolio

10.9.4. Financial

10.9.5. Recent Industry Insights

10.9.6. SWOT Analysis

10.10. Brilliant Pharmaceuticals

10.10.1. Company Basic Information and Sales Area

10.10.2. Main Business/Business Overview

10.10.3. Product Portfolio

10.10.4. Financial

10.10.5. Recent Industry Insights

10.10.6. SWOT Analysis

10.11. Sihuan Pharma

10.11.1. Company Basic Information and Sales Area

10.11.2. Main Business/Business Overview

10.11.3. Product Portfolio

10.11.4. Financial

10.11.5. Recent Industry Insights

10.11.6. SWOT Analysis

10.12. Salubris

10.12.1. Company Basic Information and Sales Area

10.12.2. Main Business/Business Overview

10.12.3. Product Portfolio

10.12.4. Financial

10.12.5. Recent Industry Insights

10.12.6. SWOT Analysis

10.13. Sino Biopharm

10.13.1. Company Basic Information and Sales Area

10.13.2. Main Business/Business Overview

10.13.3. Product Portfolio

10.13.4. Financial

10.13.5. Recent Industry Insights

10.13.6. SWOT Analysis

10.14. CSPC

10.14.1. Company Basic Information and Sales Area

10.14.2. Main Business/Business Overview

10.14.3. Product Portfolio

10.14.4. Financial

10.14.5. Recent Industry Insights

10.14.6. SWOT Analysis

10.15. FS Pharmatech

10.15.1. Company Basic Information and Sales Area

10.15.2. Main Business/Business Overview

10.15.3. Product Portfolio

10.15.4. Financial

10.15.5. Recent Industry Insights

10.15.6. SWOT Analysis

10.16. Novartis

10.16.1. Company Basic Information and Sales Area

10.16.2. Main Business/Business Overview

10.16.3. Product Portfolio

10.16.4. Financial

10.16.5. Recent Industry Insights

10.16.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Sacubitril Valsartan Sodium Market

Figure 4: Global Sacubitril Valsartan Sodium Market: Drivers

Figure 5: Global Sacubitril Valsartan Sodium Market: Challenges

Figure 6: Global Sacubitril Valsartan Sodium Market: Trends

Figure 7: Global Sacubitril Valsartan Sodium Market: Opportunity

Figure 8: Global Sacubitril Valsartan Sodium Market: Restraint

Figure 9: Global Sacubitril Valsartan Sodium Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Types

Figure 17: Global Market Share (%) By Types (2024)

Figure 18: Global Sacubitril Valsartan Sodium Market Value (USD Million) By Region

Figure 19: Global Sacubitril Valsartan Sodium Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Types

Figure 25: Global Market Share (%) By Types (2032)

Figure 26: Global Sacubitril Valsartan Sodium Market Value (USD Million) By Region

Figure 27: Global Sacubitril Valsartan Sodium Market Share (%) By: Regions (2032)

Figure 28: Global Sacubitril Valsartan Sodium Market Volume (K) By Region

Figure 29: Global Sacubitril Valsartan Sodium Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Types

Figure 35: Global Market Share (%) By Types (2032)

Figure 36: Global Sacubitril Valsartan Sodium Market Value (USD Million) By Region

Figure 37: Global Sacubitril Valsartan Sodium Market Share (%) By: Regions (2032)

Figure 38: Global Sacubitril Valsartan Sodium Market Volume (K) By Region

Figure 39: Global Sacubitril Valsartan Sodium Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

127 items

Table 1: Market Segmentation Analysis

Table 2: Global Sacubitril Valsartan Sodium Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Sacubitril Valsartan Sodium Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Sacubitril Valsartan Sodium Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Types

Table 12: Global Market Share (%) By Types (2024)

Table 13: Global Sacubitril Valsartan Sodium Market Value (USD Million) By Region

Table 14: Global Sacubitril Valsartan Sodium Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Types

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Types

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Types

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 30: Global Sacubitril Valsartan Sodium Market Volume (K) By Region

Table 31: Global Sacubitril Valsartan Sodium Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Types

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Types

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Types

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Types

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Types

Table 47: Global Sacubitril Valsartan Sodium Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Sacubitril Valsartan Sodium Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Sacubitril Valsartan Sodium Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Tianyu Pharma Basic Information And Sales Area

Table 52: Tianyu Pharma. Products Portfolio

Table 53: Sepharma Basic Information And Sales Area

Table 54: Sepharma. Products Portfolio

Table 55: Wisdom Pharmaceutical Basic Information And Sales Area

Table 56: Wisdom Pharmaceutical. Products Portfolio

Table 57: Qilu Pharma Basic Information And Sales Area

Table 58: Qilu Pharma. Products Portfolio

Table 59: SPH Basic Information And Sales Area

Table 60: SPH. Products Portfolio

Table 61: Zhongdan Group Basic Information And Sales Area

Table 62: Zhongdan Group. Products Portfolio

Table 63: Kelun Basic Information And Sales Area

Table 64: Kelun. Products Portfolio

Table 65: Rundu Pharma Basic Information And Sales Area

Table 66: Rundu Pharma. Products Portfolio

Table 67: Disha Pharmaceutical Group Basic Information And Sales Area

Table 68: Disha Pharmaceutical Group. Products Portfolio

Table 69: Brilliant Pharmaceuticals Basic Information And Sales Area

Table 70: Brilliant Pharmaceuticals. Products Portfolio

Table 71: Sihuan Pharma Basic Information And Sales Area

Table 72: Sihuan Pharma. Products Portfolio

Table 73: Salubris Basic Information And Sales Area

Table 74: Salubris. Products Portfolio

Table 75: Sino Biopharm Basic Information And Sales Area

Table 76: Sino Biopharm. Products Portfolio

Table 77: CSPC Basic Information And Sales Area

Table 78: CSPC. Products Portfolio

Table 79: FS Pharmatech Basic Information And Sales Area

Table 80: FS Pharmatech. Products Portfolio

Table 81: Novartis Basic Information And Sales Area

Table 82: Novartis. Products Portfolio

Table 83: Global Market Value (USD Million) (2025-2032) By Application

Table 84: Global Market Share (%) By Application (2032)

Table 85: Global Market Value (USD Million) (2025-2032) By Types

Table 86: Global Market Share (%) By Types (2032)

Table 87: Global Market Volume (K) (2025-2032) By Application

Table 88: Global Market Share (%) By Application (2032)

Table 89: Global Market Volume (K) (2025-2032) By Types

Table 90: Global Market Share (%) By Types (2032)

Table 91: Global Sacubitril Valsartan Sodium Market Value (USD Million) By Region

Table 92: Global Sacubitril Valsartan Sodium Market Share (%) By Region (2025-2032)

Table 93: North America Market Value (USD Million) (2025-2032) By Country

Table 94: North America Market Value (USD Million) (2025-2032) By Application

Table 95: North America Market Value (USD Million) (2025-2032) By Types

Table 96: Europe Market Value (USD Million) (2025-2032) By Country

Table 97: Europe Market Value (USD Million) (2025-2032) By Application

Table 98: Europe Market Value (USD Million) (2025-2032) By Types

Table 99: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 100: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 101: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 102: South America Market Value (USD Million) (2025-2032) By Country

Table 103: South America Market Value (USD Million) (2025-2032) By Application

Table 104: South America Market Value (USD Million) (2025-2032) By Types

Table 105: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 106: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 107: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 108: Global Sacubitril Valsartan Sodium Market Volume (K) By Region

Table 109: Global Sacubitril Valsartan Sodium Market Share (%) By Region (2025-2032)

Table 110: North America Market Volume (K) (2025-2032) By Country

Table 111: North America Market Volume (K) (2025-2032) By Application

Table 112: North America Market Volume (K) (2025-2032) By Types

Table 113: Europe Market Volume (K) (2025-2032) By Country

Table 114: Europe Market Volume (K) (2025-2032) By Application

Table 115: Europe Market Volume (K) (2025-2032) By Types

Table 116: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 117: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 118: Asia Pacific Market Volume (K) (2025-2032) By Types

Table 119: South America Market Volume (K) (2025-2032) By Country

Table 120: South America Market Volume (K) (2025-2032) By Application

Table 121: South America Market Volume (K) (2025-2032) By Types

Table 122: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 123: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 124: Middle East & Africa Market Volume (K) (2025-2032) By Types

Table 125: Research Programs/Design For This Report

Table 126: Key Data Information From Secondary Sources

Table 127: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Sacubitril Valsartan Sodium Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	5.60 billion
Revenue forecast in 2033	21.77 billion
Growth rate	CAGR of 18.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Tianyu Pharma; Sepharma; Wisdom Pharmaceutical; Qilu Pharma; SPH; Zhongdan Group; Kelun; Rundu Pharma; Disha Pharmaceutical Group; Brilliant Pharmaceuticals; Sihuan Pharma; Salubris; Sino Biopharm; CSPC; FS Pharmatech; Novartis
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options